While cost discipline and licensing revenue signal operational improvement, the company's $3.3 million cash position remains insufficient for long-term viability without additional financing. Traders should monitor upcoming FDA engagement and potential capital raises, as liquidity risk continues to overshadow clinical progress.
Price Chart
Executive Summary
Apollomics reported a $8.5 million revenue gain from a licensing deal with LaunXP, a 64% reduction in operating expenses, and narrowed net loss from $53.9M to $10.9M in 2025. However, cash remains critically low at $3.3 million as of year-end, and the company continues to face going concern risks. Clinical progress on vebreltinib continues with global Phase 2 trials and planned IND submission in 2027.
Key Facts
- Revenue increased to $8.5 million in 2025 from $0 in 2024 due to upfront payment from LaunXP licensing agreement for vebreltinib in Asia (ex-China, HK, Macau).
- Net loss narrowed to $10.9 million in 2025 from $53.9 million in 2024, driven by 64% YoY decline in operating expenses to $19.8 million.
- Cash and equivalents decreased to $3.3 million as of December 31, 2025, down from $9.8 million at end of 2024, despite $4.1 million PIPE raise in September 2025.
- Vebreltinib (APL-101) is in ongoing global Phase 2 SPARTA trial with over 282 patients enrolled; FDA submission for accelerated approval anticipated in first half of 2027.
- Company resolved Cayman litigation and cleared legacy obligations, part of strategic turnaround under new management team.
Financial Impact
$8.5 million in new licensing revenue, $34.9 million reduction in net loss, but cash burn resulted in only $3.3 million cash on hand by year-end
Risk Factors
- Going concern risk persists due to low cash reserves ($3.3M) relative to ongoing R&D and operating needs.
- Future funding needs may lead to dilutive equity offerings or reliance on related-party financing.
- Clinical development timelines for vebreltinib remain multi-year, with no near-term commercial revenue expected ex-China.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-179094 |
| Document: aplm-6k-apr26.htm | 0001193125-26-179094 |
| Document: 0001193125-26-179094-index-headers.html | 0001193125-26-179094 |
| Document: 0001193125-26-179094-index.html | 0001193125-26-179094 |
| Document: 0001193125-26-179094.txt | 0001193125-26-179094 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 3, 2026 20w ago | EFFECT | $0.0139 $0.0143 | ▼ −2.88% | ▼ −0.38% | — |
Apr 27, 2026 26w ago | 6-K | $0.0139 $0.0175 | ▲ +25.90% | ▲ +21.12% | — |
Apr 24, 2026 26w ago | 20-F | $0.0139 $0.0175 | ▼ −25.90% | ▼ −21.12% | — |
Apr 1, 2026 29w ago | 6-K | $0.0139 $0.0201 | ▲ +44.60% | ▲ +30.44% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers